Loading...

Tekla Healthcare Investors

HQH•NYSE
Financial Services
Asset Management
$15.49
$-0.04(-0.26%)

Tekla Healthcare Investors (HQH) Stock Overview

Explore Tekla Healthcare Investors’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B+

Score: 79.1/100

Key Financials

Market Cap835.4M
P/E Ratio4.49
EPS (TTM)$0.13
ROE0.18%
Fundamental Analysis

AI Price Forecasts

1 Week$15.23
1 Month$16.26
3 Months$17.34
1 Year Target$18.63

HQH Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Tekla Healthcare Investors (HQH) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $18.63.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 4.49 and a market capitalization of 835.4M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Revenue Growth
4.64%
↑ 4.64%
Profit Growth
$3.45
↑ 228.30%
EPS Growth
$3.45
↑ 211.40%
Operating Margin
-2.05%
↑ 81.42%
ROE
17.89%
↑ 228.30%
Dividend Yield
0.00%
Analyst Recommendations data is not available for HQHAnalyst Recommendations details for HQH are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Tekla Healthcare Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the healthcare sector, including the biotechnology, medical devices, and pharmaceuticals industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as current or anticipated market position for services or products, experienced business management, recognized technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotechnology Index, the S&P 500 Index, and the S&P 1500 Healthcare Index. It was previously known as H&Q Healthcare Investors. Tekla Healthcare Investors was formed on October 31, 1986 and is domiciled in the United States.

CEO

Daniel R. Omstead M.S,

Headquarters

100 Federal Street, Boston, MA

Founded

1987

Frequently Asked Questions

;